pharmaphorum

NOVEMBER 17, 2022

Leela Barham argues that more transparency at a minimum is required next time around, should a VPAS style of agreement be agreed upon for 2024 onwards, and perhaps even a more radical re-think about how a deal is struck in the future. Initial forecast growth rate of measured sales. Actual growth rate of measured sales.

Government 97

Government Sales Medicine Consulting 97

PM360

MARCH 22, 2024

Also, these CRMs must differentiate from sales CRMs because the type of knowledge capture is significantly different. MSL insights have the potential to deepen relationships with HCPs, ultimately enhancing patient health outcomes.

Medical 52

Medical Education Medical science Sales 52

PM360

APRIL 7, 2023

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. The business-to-business market leaders must find new and creative ways to help patients receive their treatments. The 340B battle will rage on.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

pharmaphorum

JULY 11, 2022

NICE has updated its recommendations for NHS use of Johnson & Johnson’s IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible for treatment with the drug. J&J recorded worldwide Tremfya sales of $590 million in the first three months of 2022.

Patients 52

Patients Competition Marketing Sales 52

pharmaphorum

JULY 11, 2022

The company had been eyeing a possible regulatory filing for fitusiran this year, but has now set back the timeline – possibly until 2024 – while it gathers data on the revised dosing schedule, in the hope of maintaining efficacy with fewer clotting side effects. Sanofi acquired the drug when it bought Bioverativ in 2018 for $11.6

Engineering 52

Engineering Side effects Competition Sales 52

pharmaphorum

JANUARY 16, 2023

The bi-weekly intramuscular shot – which was also approved in China in 2021 – will enter a crowded market for long-acing injectable (LAI) schizophrenia therapies in the US and have to take on heavyweight competition, including drugs that require less frequent dosing.

FDA 52

FDA Pharma Marketing Competition 52

pharmaphorum

JANUARY 13, 2023

California Attorney General Rob Bonta (pictured above) said the conduct of the companies amounts to unlawful and deceptive business practices that violate the state’s unfair competition laws. The suit follows legal action over insulin pricing taken by other states, including Arkansas , Kansas, Mississippi, and Minnesota.

Manufacturing 103

Manufacturing Patients Medical Competition 103

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Marketing 52

Marketing Physicians Sales Leads 52

PM360

MAY 21, 2024

Gone are the days of relying solely on direct sales representatives and mass advertising to reach healthcare professionals (HCPs) and consumers. In an era defined by digital disruption and shifting consumer expectations, pharmaceutical marketers must embrace innovative strategies to stay relevant and competitive.

Marketing 52

Marketing Pharmaceutical Distribution Healthcare 52

pharmaphorum

JANUARY 24, 2023

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

Medicine 93

Medicine Healthcare Healthcare Pharma 93

Pharmaceutical Technology

OCTOBER 28, 2022

According to GlobalData, Pharmaceutical Technology’s parent company, Prevnar 13 and Vaxneuvance are forecasted to have global sales of $7.26 VAX-24 has forecasted sales of $21 million in the same year. The company expects to hold regulatory talks to shape its incoming Phase III program in adult patients in the second half of 2023.

Training 64

Training Marketing Competition FDA 64

Infuse Medical

FEBRUARY 23, 2021

The Grand View Forecast states that the global market for medical animation is worth $514 million by 2024. Use 3D Animation to Educate Professionals and Patients. So, if you’re in medical device sales, get a 3D educational video made for your product that does both a thousand-yard view and an in-depth presentation.

Medical 52

Medical Education Sales Marketing 52

PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. ABIGAIL MALLON Chief Patient Experience Officer, VMS BioMarketing Physician burnout is on the rise. The second to increase in patient-oriented communication and support for physicians.

Education 59

Education Physicians Healthcare Healthcare 59

Evolve Your Success

APRIL 11, 2023

Building your brand in medical device sales requires experience, strategic insights, and a relentless pursuit of excellence. With 40 years of medical device sales experience, Pat discusses how to build a successful medical device sales business. He also touches on the sales funnel, the art of hiring, and more.

Sales 52

Sales Medical Medical sales Media 52

Evolve Your Success

JANUARY 10, 2024

The magic about medical device sales is that anyone can get into the industry no matter the background; all it takes is having passion, commitment, and work ethic. At just 19 years old, Travis Harvey has created an entirely new life for himself getting into orthopedic medical device sales under Joey Testa. What could happen?

Sales 52

Sales Medical Medical sales Doctors 52

Evolve Your Success

FEBRUARY 27, 2024

If you are looking for inspiration to go from medical sales to medical entrepreneurship, this is the episode for you. Samuel Adeyinka introduces us to Tim Lew , who takes us on a journey through his unique academic background to a successful career in medical device sales and distributorship. We have with us another special guest.

Medical sales 52

Medical sales Medical Sales Education 52

Medico Reach

FEBRUARY 8, 2023

billion during 2020-2024. Big data can help clinical trial design, allowing researchers to leverage genetic makeup, historical patient data, past trial results, demographics, and more to find the right participants. Pharma companies can utilize big data to predict the sale of a particular medicine owing to various demographic factors.

Pharma 52

Pharma Medicine Marketing Prospecting 52

PM360

SEPTEMBER 28, 2022

Patient behavior on insulin: Part D plans will have limited opportunity to adjust strategy for 2023, given bids are locked in. Behavioral response (patient adherence/persistence) to a lower out-of-pocket cost for insulin is unknown. Maximum patient Part D out-of-pocket set at $2,000.

Government 97

Government Manufacturing Prescription Competition 97

pharmaphorum

JULY 19, 2022

That came after a protracted period of underperforming sales and operating profits in recent years, mainly due to pricing pressures. In its second-quarter results update (PDF) this morning, Novartis reported first half sales of $4.68 In its second-quarter results update (PDF) this morning, Novartis reported first half sales of $4.68

Sales 96

Sales Competition Medicine Pharma 96

pharmaphorum

JUNE 29, 2022

The layoffs – originally reported by TagesAnzeiger and citing unnamed sources – are part of a cost-reduction programme announced in April aimed at trimming at least $1 billion by 2024 off the group’s annual expenditures. If confirmed, the reductions would be equivalent to around 7.4%

Sales 95

Sales Competition Management Marketing 95

Pharmaceutical Technology

SEPTEMBER 26, 2022

Sandoz has a strong global brand and a unique heritage in areas ranging from generic antibiotics to biosimilars; it is also determined to differentiate itself as the off-patent company with the greatest focus on identifying and meeting patient needs.”. Strong competition limits Sandoz's growth. The site employs around 250 people.

Competition 64

Competition Manufacturing Marketing Distribution 64

Pharmaceutical Technology

MAY 5, 2023

To keep within this limit, pharmaceutical companies have had to pay rebates on their sales back to the NHS on all expenditures above the capped limit. In recent years, medical sales have grown rapidly, and the scheme has adjusted to this growth. The revised voluntary scheme has an expected launch on January 1, 2024.

Government 52

Government Medicine Pharmaceutical Medical sales 52

Clarivate

DECEMBER 14, 2023

Pharmaceutical benefit managers, M&A activity among integrated delivery networks, disruption by nontraditional healthcare entities, enrollment, and the 2024 presidential election are five areas to pay attention to moving into 2024. Clarivate experts explain why these topics are ones to watch in 2024.

Marketing 52

Marketing Healthcare Healthcare Insurance 52